Automating Endocrinology Carelon Prior Authorizations

Klivira streamlines **endocrinology Carelon** prior authorizations, accelerating access to critical therapies like GLP-1s, CGMs, and insulin pumps by automating policy adherence and documentation.

Prior authorization for endocrinology treatments, especially those managed by Carelon (Elevance Health's utilization management subsidiary), presents significant administrative burdens for clinics and health systems. The high volume of GLP-1 agonists, continuous glucose monitors (CGMs), and insulin pumps, coupled with Carelon's specific medical policies, often leads to delays and denials. Klivira's platform integrates directly into your existing EMR workflows to intelligently manage these complex requirements.

The Challenge of Endocrinology Prior Authorizations with Carelon

Endocrinology practices face unique complexities in prior authorization, driven by rapidly evolving treatment landscapes and payer-specific criteria. Carelon, as a major utilization management entity, applies detailed medical policies for high-cost medications and devices critical for diabetes and other endocrine conditions. Navigating these policies manually can strain revenue cycle operations, impacting patient care access and staff efficiency.

Common Endocrinology Therapies Requiring Carelon PA

GLP-1 receptor agonists (e.g., Ozempic, Mounjaro, Zepbound, Wegovy)
Dual GIP/GLP-1 agonists (e.g., tirzepatide)
SGLT2 inhibitors (e.g., Jardiance, Farxiga)
Continuous Glucose Monitoring (CGM) systems (e.g., Dexcom G7, FreeStyle Libre 3)
Insulin pumps and tubeless systems (e.g., Tandem t:slim X2, Omnipod 5)
Growth hormone therapies (e.g., somatropin biosimilars)

Carelon's Utilization Management for Endocrinology Treatments

Carelon's (formerly AIM Specialty Health) utilization management programs are designed to ensure medical necessity for a wide range of endocrinology services, including advanced pharmaceuticals and durable medical equipment. Their policies often reference clinical guidelines from bodies like the ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines. Compliance requires precise documentation of patient history, prior medication trials (step therapy), specific diagnostic criteria (e.g., A1c, BMI, eGFR, IGF-1 levels), and evidence of patient adherence.

Klivira's Automated Solution for Endocrinology Carelon PAs

Klivira's platform is engineered to address the specific demands of **endocrinology Carelon** prior authorizations. By integrating with your EMR, we capture clinical data to automatically populate and submit PA requests via ePA (NCPDP SCRIPT and X12 278) or directly through payer portals. Our system incorporates ADA/AACE-guideline-aware step-therapy logic, GLP-1 indication-specific routing (T2D vs. obesity), and manages re-authorization cycles for devices like CGMs and insulin pumps, including adherence documentation.

Key Documentation Automated for Carelon Endocrinology Submissions

A1c levels and prior medication trials for GLP-1 RAs and SGLT2 inhibitors
BMI criteria and documentation of prior weight-management interventions for obesity medications
Diabetes diagnosis, insulin-requiring status, and hypoglycemia history for CGM coverage
Insulin-requirement documentation, prior MDI trials, and patient training for insulin pumps
Diagnostic documentation (e.g., GH stimulation testing, IGF-1 levels) for growth hormone therapy
Compliance with biosimilar substitution requirements for insulin and growth hormone

Optimizing Workflow and Reducing Denials for Endocrinology Carelon PAs

Klivira helps endocrinology practices mitigate common denial reasons such as GLP-1 obesity-indication coverage gaps, step therapy non-compliance, and insufficient documentation for CGMs in non-insulin-requiring T2D patients. By automating the evidence collection and submission process, we empower your team to focus on patient care, reduce administrative overhead, and improve first-pass approval rates for critical endocrine therapies.

Frequently asked questions

What specific endocrinology medications does Klivira automate for Carelon?

Klivira automates prior authorizations for a broad range of endocrinology medications and devices, including GLP-1 receptor agonists (e.g., Ozempic, Mounjaro, Zepbound), SGLT2 inhibitors, various insulins, continuous glucose monitors (CGMs), and insulin pumps, all while adhering to Carelon's specific medical policies.

How does Klivira handle Carelon's step therapy requirements for GLP-1s?

Klivira's platform incorporates intelligent logic to manage Carelon's step therapy requirements for GLP-1s. It identifies necessary prior medication trials (e.g., metformin) and ensures that documentation of these trials or contraindications is automatically included in the PA submission, aligning with payer and clinical guidelines.

Can Klivira manage re-authorizations for CGMs and insulin pumps with Carelon?

Yes, Klivira is designed to manage periodic re-authorization cycles for devices like CGMs and insulin pumps. Our system tracks re-authorization dates and prompts for necessary adherence documentation and clinical updates, ensuring continuous coverage with Carelon.

What EMR integrations support endocrinology PA workflows with Carelon?

Klivira integrates with leading EMR systems via SMART on FHIR and other secure methods to seamlessly pull patient data relevant for endocrinology prior authorizations. This integration streamlines the data collection process for Carelon submissions, reducing manual data entry and potential errors.

How does Klivira address the variability in Carelon's obesity medication coverage?

Klivira's policy engine continuously tracks payer-specific coverage for anti-obesity medications, including those managed by Carelon. The platform guides users on specific BMI criteria, required prior weight-management interventions, and relevant documentation, helping to navigate the wide variability in coverage policies.